Navigation Links
New Roche Dual Target HIV-1 Test Approved for Use in European Union
Date:12/15/2008

and customizable to meet the space and workflow needs of any laboratory. In 2005, Roche received CE Mark certification for the full viral load monitoring menu (HIV-1, HBV, and HCV) on the system.

About HIV-1

According to estimates by the World Health Organization (WHO) and UNAIDS, 33.2 million people were living with HIV at the end of 2007. That same year, some 2.5 million people became newly infected, and 2.1 million died of AIDS, including 330,000 children.

The human immunodeficiency virus (HIV) is a retrovirus that infects cells of the human immune system, destroying or impairing their function. In the early stages of infection, the person has no symptoms. Within 10-15 years an HIV infection will develop into acquired immunodeficiency syndrome (AIDS); antiretroviral drugs can slow down this process even further.

HIV is transmitted through unprotected sexual intercourse (anal or vaginal), transfusion of contaminated blood, sharing of contaminated needles, and between a mother and her infant during pregnancy, childbirth and breastfeeding.

The ability of HIV to mutate itself in the presence of antiretroviral drugs can lead to treatment failure, increased direct and indirect health costs associated with the need to start more costly second-line treatment for patients, the spread of resistant strains of HIV and the need to develop new anti-HIV drugs.(1)

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagno
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Improved Testing for Hepatitis B Virus From Roche
2. Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals
3. Roche Holds Sixth Annual Childrens Walk in Nutley
4. New Jersey Jury Awards $12.9 Million to Three Patients Whose Use of Roche Acne Medication Accutane Found to Cause Severe Bowel Illness
5. Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales
6. Primary Insomnia Tied to Brain Neurochemical Imbalance
7. Study links primary insomnia to a neurochemical abnormality in young and middle-aged adults
8. Roche Receives FDA Approval for Hepatitis C Viral Load Test on Its Fully Automated Real-Time PCR Platform
9. Rochester Medical Announces Fourth Quarter 2008 Earnings Conference Call November 6, 2008
10. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
11. Balloon Manor Reappears in Rochester
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... ... ZH Healthcare announces a new cloud based service delivering Health IT as ... Service (HITaaS) is a Healthcare dedicated cloud based service that sits over infrastructure as ... all aspects of infrastructure, security, runtime, middleware, OS, virtualization, Servers, storage, contracts, and ...
(Date:7/31/2015)... ... ... therapy for knee osteoarthritis is an important part of knee pain treatment. ... doing what they want or need to do. The patient may have trouble getting in ... exercise regime may be limited by the pain in their knee. When a patient sees ...
(Date:7/31/2015)... ... , ... New Energy Works Timberframers invites the public to join their timber ... from 9am – 12pm. Timber frame raisings are special, celebrating both craft ... the culmination of months of effort, planning, fundraising, and dreaming takes shape. , ...
(Date:7/31/2015)... , ... July 31, 2015 , ... The Radiology ... Michael Burgess, MD, (R-Tex) presenting “What’s Next for Health Care: A View From Capitol ... and founder of the Congressional Health Caucus, Rep. Burgess has a special understanding of ...
(Date:7/31/2015)... ... ... “ Crack’em ” was featured on NewsWatch as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... can be a very messy experience, especially when cracking eggs. Cracking an egg is ...
Breaking Medicine News(10 mins):Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Make Less Mess while Cooking with Crack’em 2
... 26 Daniel S. Dueber, CEO of Coast Independent Review ... Investigations of the House Energy and Commerce Committee in the ... the Government Accountability Office (GAO) in a clandestine sting operation ... out despite the absence of proof that Coast had committed ...
... free radicals, researchers say , , THURSDAY, March 26 ... influence children,s lung growth and function, as well ... say University of Southern California researchers. , "Many ... genetic variation and environmental exposures such as tobacco ...
... Boston Scientific Corporation (NYSE: BSX ) today ... news announcements at the 58th Annual Scientific Session of ... runs from March 28-31 in Orlando, Florida. "We are ... from the landmark SYNTAX study, the only randomized trial ...
... Group, Inc. (NYSE Amex: QGP ) ( ... RedChip Companies Inc. to enhance its investor relations outreach ... in broadening visibility for emerging growth companies as well ... comprehensive platform of media services," said Noel J. Guillama, ...
... GUANGZHOU, China, March 26 /PRNewswire-Asia / -- ... Medicine" or "the Company"), a,developer and a ... Chinese medicines ("TCM"),nutritional and dietary-supplements, medical devices, ... China ("PRC"), today reported outstanding,financial results for ...
... is Alcohol Awareness MonthSEYMOUR, Tenn., March 26 Six ... on alcohol, according to the National Center on Addiction ... binge drinking in women,s colleges increased by 124 percent ... in need of but have not received treatment for ...
Cached Medicine News:Health News:Coast IRB Tells Congressional Committee Sting Operation Was Illegal, Unnecessarily Harmful 2Health News:Genes May Boost Harm to Kids From Secondhand Smoke 2Health News:Boston Scientific Announces Schedule For ACC 2009 2Health News:Boston Scientific Announces Schedule For ACC 2009 3Health News:Boston Scientific Announces Schedule For ACC 2009 4Health News:Boston Scientific Announces Schedule For ACC 2009 5Health News:Boston Scientific Announces Schedule For ACC 2009 6Health News:The Quantum Group Announces Engagement of RedChip Companies for Investor Relations Programs 2Health News:The Quantum Group Announces Engagement of RedChip Companies for Investor Relations Programs 3Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 2Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 3Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 4Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 5Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 6Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 7Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 8Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 9Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 10Health News:China Medicine Announces Record Fourth Quarter and 2008 Results 11Health News:Is it Really About Alcohol? The Truth About Alcohol Abuse in Women 2Health News:Is it Really About Alcohol? The Truth About Alcohol Abuse in Women 3
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... FRANCISCO , July 30, 2015 ... market is expected to reach USD 23.01 million ... View Research, Inc. Growing base of geriatric population, increasing ... infections, and rising level of awareness among target customer ... rendering drivers over the forecast period. According to estimates ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5
... Cloud-based Veeva CRM Now Deployed in Over 20 European ... Customer Summit kicking off this morning in Philadelphia, Veeva Systems ... Since Veeva,s official expansion into Europe in April 2010, the ... than 35 life sciences companies across 20+ different European markets. ...
... AB (OMX: MVIR), a research-based specialty pharmaceutical company focused ... Henric Juserius to be the new head of the ... for Medivir,s pharmaceutical marketing and sales, will join the ... the management team. Henric Juserius has a ...
Cached Medicine Technology:Veeva Systems Announces Dramatic Growth in Europe 2Veeva Systems Announces Dramatic Growth in Europe 3Veeva Systems Announces Dramatic Growth in Europe 4New Executive Vice President Commercial Appointed 2
All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheostat for fine control of il...
Otoscope with 4X magnification lens, swivellable to both sides, with removable cover glass to insert external instruments. Sealed system allowing for pneumatic otoscopy. 3.5V halogen source....
Otoscope with 4X magnification lens, swivellable to both sides, with removable cover glass to insert external instruments. Sealed system allowing for pneumatic otoscopy. 2.5V halogen source....
All metal construction with fiber optic illumination. Large diameter viewing port, insufflation port, and swivelling airtight window....
Medicine Products: